Reducing immune inhibition induced by SIGLEC-15
AssigneeInnovative Cellular Therapeutics Holdings, Ltd.
InventorsZhiyuan Cao, Chengfei Pu, Lei Xiao
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a modified cell comprising a polynucleotide encoding a secretable scFv binding SIGLEC-15 and/or encoding a dominant negative form of CD44. In embodiments, the modified cell further comprises an antigen-binding molecule, which for example, is a CAR comprising an antigen-binding domain, a transmembrane domain, and an intracellular signaling domain.
Claims22
A modified cell comprising a polynucleotide encoding an antibody binding SIGLEC-15, wherein the antibody is secretable or attached to the membrane of the modified cell, wherein the polynucleotide comprises a polynucleotide encoding at least one of SEQ ID NOS:
- 115 and 116.
A modified cell comprising a polynucleotide encoding at least one of SEQ ID NOS:
- 117, 118, and 119.
Dependencies are inferred from the claim text.